Pfizer (PFE) Long-Term Investments (2009 - 2026)

Pfizer has disclosed Long-Term Investments across 18 years of filings, most recently posting $1.6 billion for Q1 2026.

• In Q1 2026, Long-Term Investments fell 19.27% year-over-year to $1.6 billion; the TTM figure through Mar 2026 stood at $1.6 billion (down 19.27% YoY), while the FY2025 annual figure was $1.6 billion, down 27.24% from the prior year.
• Long-Term Investments steadied at $1.6 billion in Q1 2026, from $1.6 billion in the prior quarter.
• Over the last five years, Long-Term Investments for PFE reached as high as $16.0 billion in Q2 2022 and fell as low as $224.0 million in Q2 2025.
• The 5-year median for Long-Term Investments is $9.8 billion (2022), against an average of $8.0 billion.
• Annual changes were most pronounced in 2022 — Long-Term Investments soared 87.23% — and 2025, when it slumped 97.13%.
• A 5-year view of Long-Term Investments shows it stood at $10.8 billion in 2022, then jumped by 41.98% to $15.4 billion in 2023, then slumped by 85.5% to $2.2 billion in 2024, then slipped by 27.24% to $1.6 billion in 2025, then advanced by 0.31% to $1.6 billion in 2026.
• According to Business Quant data, Long-Term Investments over the past three periods registered $1.6 billion, $1.6 billion, and $2.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.